UDD Logo
CRIS - Current Research Information System
New user? Click here to register.Have you forgotten your password?
Communities & Collections
Research Outputs
Fundings & Projects
Researchers
Datasets
Statistics
  1. Home
  2. CRIS
  3. Publications
  4. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America
Details

Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America

Journal
Journal of Antimicrobial Chemotherapy
ISSN
0305-7453
1460-2091
Date Issued
2020
Author(s)
Betsy E Castro
Maritza Berrio
Monica L Vargas
Lina P Carvajal
Lina V Millan
Rafael Rios
Angie K Hernandez
Sandra Rincon
Paola Cubides
Erika Forero
An Dinh
Carlos Seas
MUNITA SEPULVEDA, JOSE MANUEL  
Facultad de Medicina Clínica Alemana Universidad del Desarrollo  
Cesar A Arias
Jinnethe Reyes
Lorena Diaz
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85089807469
WoS ID
WOS:000574367100008
DOI
10.1093/jac/dkaa221
URL
https://investigadores.udd.cl/handle/123456789/4551
URL Institutional Repository
http://hdl.handle.net/11447/4225
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006–08 and 2011–14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006–08 and 2011–14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87–0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.</jats:p></jats:sec>
Cite this document
Castro, B. E., Berrio, M., Vargas, M. L., Carvajal, L. P., Millan, L. V., Rios, R., Hernandez, A. K., Rincon, S., Cubides, P., Forero, E., Dinh, A., Seas, C., Munita, J. M., Arias, C. A., Reyes, J., & Diaz, L. (2020). Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America. Journal of Antimicrobial Chemotherapy, 75(9), 2424-2431. https://doi.org/10.1093/jac/dkaa221
Subjects
anti-bacterial agents

; 

humans

; 

latin america

; 

methicillin-resistant staphylococcus aureus

; 

microbial sensitivity tests

; 

staphylococcal infections

; 

staphylococcus aureus

; 

vancomycin

; 

bacterial protein

; 

chloramphenicol

; 

ciprofloxacin

; 

clindamycin

; 

cotrimoxazole

; 

daptomycin

; 

erythromycin

; 

gentamicin

; 

lincosamide

; 

linezolid

; 

macrolide

; 

mikamycin b

; 

minocycline

; 

rifampicin

; 

teicoplanin

; 

tetracycline

; 

vancomycin

; 

antiinfective agent

; 

vancomycin

; 

amino acid substitution

; 

antibiotic resistance

; 

antibiotic resistome

; 

antibiotic sensitivity

; 

argentina

; 

article

; 

bacterial genome

; 

bacterium detection

; 

bacterium identification

; 

bacterium isolate

; 

brazil

; 

chile

; 

clonal species

; 

colombia

; 

computer model

; 

controlled study

; 

ecuador

; 

epsilometer test

; 

evaluation study

; 

genetic procedures

; 

guatemala

; 

heterogeneous vancomycin intermediate staphylococcus aureus

; 

macro method

; 

methicillin resistant staphylococcus aureus

; 

mexico

; 

nonhuman

; 

peru

; 

phenotype

; 

phylogeny

; 

population analysis profile method

; 

staphylococcus aureus

; 

vancomycin resistance

; 

vancomycin susceptible staphylococcus aureus

; 

venezuela

; 

whole genome sequencing

; 

genetics

; 

human

; 

microbial sensitivity test

; 

south and central america

; 

staphylococcus aureus

; 

staphylococcus infection
Logo Universidad de Desarrollo
Encuéntranos en:

Sede Santiago

Av. Plaza 680, Las Condes

Contacto|Mapa

Sede Concepción

Ainavillo 456, Concepción

Contacto|Mapa

Hosting & SupportLogo Scimago Lab

Built with DSpace-CRIS software - Extension maintained and optimized by 4science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify